Morgan Stanley
RNTX

Morgan Stanley’s Rein Therapeutics RNTX Stock Holding History

Morgan Stanley’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Buy
+14,318
New +$17.3K ﹤0.01% 6920
2025
Q2 		– Sell
-4,300
Closed -$7.61K – 8329
2025
Q1 		$7.61K Hold
4,300
– – ﹤0.01% 6883
2024
Q4 		$9.89K Sell
4,300
-1,250
-23% -$3.79K ﹤0.01% 6804
2024
Q3 		$19.6K Buy
5,550
+4,300
+344% +$11.5K ﹤0.01% 6507
2024
Q2 		$3.46K Hold
1,250
– – ﹤0.01% 6947
2024
Q1 		$8.29K Hold
1,250
– – ﹤0.01% 6764
2023
Q4 		$3.81K Hold
1,250
– – ﹤0.01% 6896
2023
Q3 		$1.9K Hold
1,250
– – ﹤0.01% 7144
2023
Q2 		$2.24K Hold
1,250
– – ﹤0.01% 7174
2023
Q1 		$1.55K Hold
1,250
– – ﹤0.01% 7285
2022
Q4 		$2.96K Sell
1,250
-1
-0.1% -$3 ﹤0.01% 7270
2022
Q3 		$5K Buy
1,251
+1
+0.1% +$4 ﹤0.01% 7262
2022
Q2 		$7K Sell
1,250
-221
-15% -$2.03K ﹤0.01% 7334
2022
Q1 		$15K Sell
1,471
-33,415
-96% -$302K ﹤0.01% 7269
2021
Q4 		$393K Buy
34,886
+32,463
+1,340% +$502K ﹤0.01% 5692
2021
Q3 		$50K Buy
2,423
+537
+28% +$11.8K ﹤0.01% 6728
2021
Q2 		$47K Buy
1,886
+1,301
+222% +$32.5K ﹤0.01% 6699
2021
Q1 		$17K Buy
+585
New +$20K ﹤0.01% 6784
2019
Q3 		– Sell
-1,475
Closed -$21K – 6784
2019
Q2 		$21K Sell
1,475
-18,432
-93% -$483K ﹤0.01% 5921
2019
Q1 		$776K Buy
19,907
+561
+3% +$17.5K ﹤0.01% 4278
2018
Q4 		$325K Sell
19,346
-2,050
-10% -$82.4K ﹤0.01% 5057
2018
Q3 		$1.18M Buy
21,396
+20,344
+1,934% +$1.37M ﹤0.01% 4410
2018
Q2 		$114K Buy
1,052
+167
+19% +$18.9K ﹤0.01% 5708
2018
Q1 		$144K Buy
885
+478
+117% +$85.2K ﹤0.01% 5600
2017
Q4 		$86K Buy
407
+85
+26% +$20.4K ﹤0.01% 5679
2017
Q3 		$86K Buy
+322
New +$80.8K ﹤0.01% 5617

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Morgan Stanley's RNTX Position: Q2 2026 in Review

Morgan Stanley opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 14,318 shares worth $14.9K. The stake represents ﹤0.01% of the portfolio and ranks #6920 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in RNTX as recently as Q1 2025.

Morgan Stanley first reported a position in RNTX in Q3 2017 and has held it in 26 quarters since. The position peaked at $1.18M in Q3 2018. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Morgan Stanley held 14,318 shares of Rein Therapeutics worth $14.9K as of Q2 2026.
  • Rein Therapeutics was a new Morgan Stanley position in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6920 holding.
  • Morgan Stanley first reported a position in Rein Therapeutics in Q3 2017 and has held it in 26 quarters since.
  • Morgan Stanley's Rein Therapeutics position peaked at $1.18M in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.